| Budget Amount *help |
¥16,900,000 (Direct Cost: ¥13,000,000、Indirect Cost: ¥3,900,000)
Fiscal Year 2019: ¥7,930,000 (Direct Cost: ¥6,100,000、Indirect Cost: ¥1,830,000)
Fiscal Year 2018: ¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2017: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
|
|---|
| Outline of Final Research Achievements |
Because inflammatory reaction is intense at acute phase of spinal cord injury (SCI), cell transplantation therapy during this stage is not effective due to low survival rate of transplanted cells. In this study, by administrating complement receptor antagonist, transplanted human iPS cell-derived neural stem cells well survived and promoted motor functional recovery when grafted even at acute phase. The antagonist suppressed the expression of inflammatory cytokines, infiltration of inflammatory cells, and the apoptosis of neural cells in the spinal cord. This histological efficacy can contribute to making a favorable environment for the transplanted cells to survive. We believe that this study will lead to future clinical application as a treatment that enhances the effect of cell transplantation for SCI.
|
